| Aug 9 |
Revelation Biosciences reports Q2 results
|
| Aug 9 |
Revelation Biosciences, Inc. Announces Financial Results for the Three and Six Months Ended June 30, 2024
|
| Jul 19 |
Revelation Biosciences files for mixed shelf offering of up to $50M
|
| Jul 8 |
REVB Releases Positive Test Results—Potential Catalyst
|
| Jun 24 |
Why Is Nano-Cap Revelation Biosciences Stock Skyrocketing On Monday?
|
| Jun 24 |
Revelation Biosciences Announces Phase 1 Clinical Study of Gemini Met the Primary Safety Endpoint and Showed Statistically Significant Biomarker Activity
|
| Jun 13 |
Revelation Biosciences Has Completed Dosing of its First in Human Phase 1 Clinical Study of Gemini
|
